Hyaluronidases.
-
PubMed
(0) (0 Votes)Views: (1) Date: (1952-1-1) Pages: () -
Author: M M RAPPORT
-
Abstract:
Related Documents
Related Groups
Related Science News
More on Sciencestage
Answers
News
- Halozyme Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Feb. 10, 2012 /PRNewswire/ --Â Halozyme Therapeutics, Inc. (NASDAQ: HALO - News) today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a price to ... - Halozyme Announces Proposed Public Offering of Common Stock
SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO - News) today announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective shelf registration ... - HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO - News) today presented interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501 (an investigational, ...
Related on Wikipedia
- Hyaluronidase - Wikipedia, the free encyclopedia
The hyaluronidases (EC 3.2.1.35) are a family of enzymes that degrade hyaluronic acid. In humans, there are six associated genes, including HYAL1, HYAL2, HYAL3, and PH-20/SPAM1. - Hyaluronan - Wikipedia, the free encyclopedia
Hyaluronan (also called hyaluronic acid or hyaluronate or HA) is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues.